GlassScriptPhysician profile
Kimberly Dobbyn
NPI 1326635392
$690.49
in general payments reported to CMS, 2019-2025
14 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $105 · 2023: $173 · 2024: $194 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $159.93 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $103.58 | 2021-2022 | |
| Abbvie INC. | $67.88 | 2022-2024 | |
| Novo Nordisk INC | $61.58 | 2023-2024 | Ozempic, Rybelsus |
| Indivior INC. | $56.82 | 2025 | Sublocade |
| Lilly USA, LLC | $53.94 | 2024 | Mounjaro, Zepbound |
| Braeburn INC. | $53.15 | 2025 | Brixadi |
| Neurocrine Biosciences, INC. | $28.11 | 2021 | |
| Axsome Therapeutics, INC. | $24.19 | 2023 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $18.82 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.25 | 2024 | Voquezna |
| Corium, LLC | $17.82 | 2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.99 | 2022 | |
| Sumitomo Pharma America, INC. | $11.43 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Dobbyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.